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Abstract 
Inflammation mediated by the immune system is known to be important in carcinogenesis and, specifically, 
T helper 17 cells have been reported to play a role in tumor progression by promoting neo-angiogenesis. 
The aim of this study was to investigate whether inflammatory cytokines and vascular endothelial growth 
factor (VEGF) levels in exhaled breath condensate (EBC) and in serum were related to tumor size in patients 
with non-small cell lung cancer (NSCLC). Il-6, IL-17, TNF-α and VEGF levels were measured in EBC and serum 
of 15 patients with stage I-IIA NSCLC and in 30 healthy controls by immunoassay. The tumor size was 
measured by a CT scan. The concentrations of IL-6, IL-17 and VEGF were significantly higher in EBC of 
patients with lung cancer, compared with controls, while only serum IL-6 concentration was higher in 
patients compared to controls. A significant correlation (r = 0.78, p = 0.001) was observed between EBC 
levels of IL-6 and IL-17; IL-17 was also correlated to EBC levels of the VEGF (r = 0.83, p < 0.001) and TNF-α 
(r = 0.62, p = 0.014). The tumor diameter was significantly correlated with EBC concentrations of VEGF (r = 
0.58, p = 0.039), IL-6 (r = 0.67, p = 0.013) and IL-17 (r = 0.66, p = 0.017). Our results show a significant 
relationship between inflammatory and angiogenic markers, measured in EBC by a non-invasive method, 
and tumor mass. 
Introduction 
Primary lung cancer is the second most frequent tumor in the world and it is the leading cause of cancer-
related death [1]. Lung cancer is linked to a long history of smoking and to its accompanying chronic 
inflammatory response [2]. Different methods for diagnosis and staging are used in clinical practice, based 
both on imaging (chest x-ray, computed tomography (CT), positron emission tomography (PET)) and blood 
tests. 
Breath analysis is an emerging approach for diagnosing and possibly for monitoring lung cancer, which can 
be applied directly to exhaled breath or to exhaled breath condensate (EBC). The advantage of breath 
analysis is that cancer-related biomarkers in exhaled breath may be related to local respiratory tract 
abnormalities and/or to cancer-related changes in blood chemistry reflected into the breath. 
Several studies have used spectrometric methods and/or chemical/nanomaterial sensor arrays [3, 4] to 
show that the profiles of volatile organic compounds (VOCs) in the breath of lung cancer patients differ 
from those of healthy persons [5]. 
It is recognized that both local and systemic inflammation mediated by the immune system play a role in 
almost every step of carcinogenesis, including tumor initiation and progression [6–8]. Specifically, T helper 
17 (Th17) cells have been recently postulated to play a key role in carcinogenesis [9, 10]. 
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Both Th17 cells and the related cytokines (IL-17 and IL-6) have been reported in different tumor tissue 
sample microenvironment, as well as in blood samples of patients with neoplastic disease [11, 12]. 
 
Increased serum IL-17 levels have been related to the spread of malignancies, including prostate, liver and 
lung cancer [13–15]. An increased number of IL-17-producing cells in neoplastic tissue has been related to 
poor survival and increased lymphangiogenesis in non-small cell lung cancer (NSCLC) [15]. 
One of the mechanisms by which IL-17 may be related to cancer diffusion and poor prognosis is its 
involvement in neo-angiogenesis. Interleukin-17 has been reported to promote the production of pro-
angiogenic factors and TNF-α in fibroblast cultures [16]. Actually IL-17 measured in cancer tissue specimens 
has been reported to be related to the number of blood vessels in ovarian, hepatocellular, gastric and 
NSCLC [14, 17–19]. 
Vascular endothelial growth factor (VEGF) is a well-known angiogenic factor, which has been linked to 
metastasis, poor prognosis and relapse of a wide variety of tumors, including lung cancer [20, 21]. 
A non-invasive method to assess lung inflammation is to obtain EBC, which collects airway lining fluid, to 
measure inflammatory markers [22]. To our knowledge, very few studies have measured cytokines in EBC 
of patients with lung cancer, finding higher concentration of IL-6, VEGF and TNF-α in patients with NSCLC 
compared to healthy subjects [23–25]. 
TNF-α, produced by both neoplastic cells and monocyte macrophage cells, has a pro-inflammatory role 
linked to all steps of tumorigenesis [26], while IL-6 is a pro-inflammatory cytokine which has been 
implicated in inflammation-associated carcinogenesis [27]. Specifically, IL-6 modulates the expression of 
genes involved in proliferation, survival and angiogenesis of tumor [28]. 
The aim of this study is to investigate whether cytokines related to Th-17 cells (IL-6, IL-17), TNF-α and VEGF 
could be measured in EBC and serum of patients with NSCLC, scheduled for curative lung resection, and 
whether the EBC levels of these cytokines might be related to the tumor mass. 
 
Materials and methods 
Patients 
Fifteen consecutive patients, admitted to the Unit of Thoracic Surgery of the University of Torino between 
January and June 2011 and scheduled for curative lung resection for NSCLC, were enrolled into the study. 
All the 15 patients were ex-smokers (mean pack-per-year: 20.2 ± 2.7). The tumor mass was located 
peripherally in all the patients. All tumor clinical stages at diagnosis were: IA in eight, IB in four and IIA in 
three patients [29]. 
Patients with asthma, COPD, interstitial lung and autoimmune diseases, those who received induction 
chemotherapy or were on therapy with oral/inhaled corticosteroids were excluded from the study, along 
with those with a recent (last 8 weeks) or current airway infection. 
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Thirty healthy subjects matched for age, gender and smoking history were enrolled as control group, 
provided that they had no cancer history, as well a recent or current airway infection. EBC and blood 
sample were collected in all the patients and controls. 
The study protocol was approved by our Institutional Review Board for human studies (n. 0039 653), and 
informed consent was obtained from all subjects. The study was conducted in accordance with the Helsinki 
Declaration. 
 
Collection of exhaled breath condensate (EBC) and blood sample 
EBC collection was performed using the disposable R TubeTM EBC collection system (Respiratory Research 
Inc., Charlottesville, VA, USA), after thorough rinsing of mouth with water, at an initial condenser 
temperature of −20 °C. Both patients and controls were investigated in the same lab room. The system 
consisted of a mouthpiece with a one-way valve and a saliva trap. The subjects, sitting and relaxed, 
breathed tidally through a disposable mouthpiece, without bacterial filter, for 10 min, wearing a nose clip. 
They kept their mouth dry during EBC collection by periodically swallowing excess saliva. A nose clip was 
also applied to exclude possible contamination of the nose. The collection was stopped in the case of 
coughing or excessive saliva and was restarted when the episode was resolved. For each patient 
approximately 2 ml of EBC was collected and the samples were immediately stored at −80 °C for later 
assays [30]. In a subset of healthy controls (n = 15) assays had been obtained after 1 and 6 months in order 
to establish the stability of stored samples (see table 1). The collected EBC samples were stored at −80 °C in 
polypropylene tubes until analysis. All EBC samples were examined for amylase activity (alpha-Amylase 
ESP1491300 kit; detection limit 0.05 mmol l−1; Boehringer Mannheim, Germany) in order to exclude 
contamination by saliva. Total protein was measured using a Quantipro BCA assay kit (Sigma Aldrich, 
Sydney, Australia); lower limit of detection 4 µg ml−1. 
 
 
A blood sample was obtained in the same day from all patients and controls and serum samples were 
immediately stored at −80 °C for later assays. 
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Cytokines assays 
A multiplex immunoassay (Bio-Rad Laboratories Inc., Hercules, CA) was used to analyze serum and EBC 
cytokines. Cytokines and VEGF were measured using an xMAP technology (Luminex Corp, Austin, TX) on a 
Bioplex 100 instrument. Data analysis was performed with Bioplex Manager 4.1 software (Bio-Rad 
Laboratories). An eight-point standard curve in duplicate was included on every 96-well plate. 
Measurements that were not on the linear part of standard curves (low concentrations) were reported as 
below the detection limit [31, 32]. 
Samples from patients and controls were analyzed on the same assay plate, evenly distributed over the 
plate. The detection limit (pg ml–1) for every variable and the percentage of the samples above the 
detection limit are reported in table 2. Results with more than 50% of the samples above the detection 
limit were used for further analysis. All cytokine and growth factor concentrations are expressed in pg ml–1. 
 
Preoperative evaluation 
Pulmonary function tests, arterial blood gas analysis, chest x-rays, chest and upper abdomen CT, 
bronchoscopy and PET scan represented the normal preoperative workup for patients with lung cancer, 
according to the more recent clinical guidelines [33]. 
CT scan 
Multislice thoracic and upper abdomen CT (Lightspeed 16Pro, GE, Milwakee, WI, USA) was performed in 
each patient. The nodule size was measured by using an electronic ruler on the workstation and recorded 
as the average of the maximal length and the width perpendicular to it. 
Statistical analysis 
Statistical analysis was performed with the aid of a commercially available statistical package (STATA 
10s). P < 0.05 was considered statistically significant. The Kolmogorov–Smirnov test was performed to 
verify the normal distribution of variables. Histogram plots appeared to have a normal distribution, except 
for serum IL-17. For the statistical analysis of this we used Mann–Whitney U tests. Two-sided independent-
sample t tests were used for analysis of the other variables with normal distribution. The correlations 
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among EBC cytokines and between EBC cytokines and tumor diameter were analyzed by linear regression 
analysis [34, 35]. 
Results 
The patients' baseline characteristics are summarized in table 3. 
 
The mean diameter of tumor was 3.28 (SD ± 2.33) cm; histological examination revealed eight 
adenocarcinoma, five squamous cell and two undifferentiated carcinoma. 
EBC cytokines: comparison between patients and controls 
In a subset of healthy controls (n = 15), cytokines and VEGF measured in aliquots of the same EBC samples 
after 1 and 6 months yielded no different results (table 1). 
Mean protein concentration of EBC samples was similar in the patients and normal controls (13 ± 2 and 14 
± 1.5 mcg ml−1, respectively – p > 0.05). 
All cytokines and VEGF were measurable in more than 50% of EBC samples of patients and controls, while 
only IL-6 and VEGF were measurable above the detection limit in the serum samples of both patients and 
controls (see table 2). The concentration of IL-6, IL-17 and VEGF were significantly higher in EBC of patients 
compared with controls, while only IL-6 serum concentration was higher in patients compared to controls 
(see table 4). No relationship was observed between serum and EBC concentration of cytokines, both in 
patients and healthy controls. 
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Inter-relationships of EBC cytokines in patients 
A significant correlation (r = 0.78, p = 0.001) was observed between EBC levels of IL-6 and IL-17 (figure 1(a)), 
which was also correlated to EBC levels of VEGF (r = 0.83, p < 0.001) (figure 1(b)). 
 
Levels of EBC IL-17 of patients were significantly correlated to TNF-α levels (r = 0.62, p = 0.014). TNF-α was 
also significantly correlated with VEGF in EBC (r = 0.62, p = 0.013). No correlations were observed among 
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serum cytokines concentrations both in patients and controls and no correlations were observed among 
EBC cytokines in controls. 
Relationship between tumor diameter and cytokines 
The tumor diameter was significantly correlated with EBC concentrations of VEGF (r = 0.58, p = 0.039) 
(figure 2), IL-6 (r = 0.67, p = 0.013) (figure 3(a)) and IL-17 (r = 0.66, p = 0.017) (figure 3(b)). No correlation 
was found between the tumor diameter and serum cytokine. 
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Discussion 
All the biomarkers were found in concentrations above the detection limit in all the EBC samples of both 
patients and controls, while in blood samples IL-17 could be measured only in 20% of samples. As EBC was 
collected without fractioning exhaled air [36], contamination from dead space could not be excluded. 
Higher levels of IL-17, IL-6 and VEGF were measured in EBC of patients with NSCLC compared to controls, 
and a significant positive correlation was observed between the tumor diameter, detected by lung CT-scan, 
and EBC levels of the above reported cytokines. Higher concentration of VEGF and IL-6 in EBC of patients 
with NSCLC compared to controls had been previously reported by Gessner et al [37] and 
Carpagnano et al [23], respectively. While VEGF levels we measured are comparable to those reported by 
Gessner, IL-6 levels reported by Carpagnano are somewhat higher than ours, possibly due to the different 
technique (specific enzyme immunoassay kit) used by Carpagnano. Conversely, to our knowledge, this is 
the first demonstration of IL-17 detection in EBC of patients with NSCLC. 
Increased levels of EBC IL-6 and IL-17 have also been observed in patients with COPD and asthma 
respectively [38–40]; that is the reason why chronic airway disease was an exclusion criterion for our 
patients. 
Our finding is particularly interesting, as IL-17 has been reported to promote the production of pro-
angiogenic factors in fibroblast cultures [16] and IL-17, measured in cancer tissue specimens, has been 
related to the number of blood vessels in a variety of tumors, including NSCLC) [14, 17–19]. Actually, the 
correlation we observed between IL-17 and VEGF and TNF-α in EBC of patients, is in agreement with the 
reported effect of IL-17 on angiogenesis. 
Of particular interest also is the correlation observed between IL-6 and IL-17 in patients' EBC, but neither in 
serum nor in control subjects 
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Luckheeram [41], in a recent review on mechanisms of differentiation of T helper lymphocytes, describes 
the role of IL-6 in the production of Th17. Interleukin 6, in synergism with TGF-β and IL-23, could stimulate 
the development and expansion of Th17. The consequent production of IL-17, in turn, would further 
increase IL-6 production, thus creating a self-maintenance cycle [42]. 
The correlation between cytokines, observed in EBC of patients, points to an inflammatory network 
promoted locally by the tumor. Unfortunately, we could not assess EBC levels of IL-23 and TGF-β, as their 
concentration was below the detection limit only in a few EBC samples (data not shown). 
We did not observe any correlation between serum and EBC levels of cytokines, suggesting that 
inflammatory changes are mainly limited to the target organ (lung) without systemic involvement, at least 
in the early stages of disease. On the other hand, increased IL-6 and IL-8 serum concentration had been 
reported in the greatest proportion of stage I NSCLC patients by Kaminska et al [43]. The high capacity of 
breath analysis to detect early lung cancer was demonstrated by Peled et al [44] who investigated the 
profiles of VOCs, determined by gas chromatography/mass spectrometry (GC-MS) combined with solid 
phase microextraction (SPME) and by a chemical nanoarray in breath samples taken from 72 patients with 
pulmonary nodules in a prospective trial. 
Actually serum IL-6 levels, a marker of non-specific inflammatory response, have been found higher in 
patients than in controls. In previous studies, increased levels of circulating proinflammatory cytokines, IL-6 
and IL-8, were reported to be associated with lung cancer [45, 46]. 
The positive relationships between the tumor diameter and EBC levels of IL-6, IL-17 and VEGF suggest that 
the same cytokines are produced either by the tumor itself or by a more extensive tissue infiltration of 
inflammatory cells. 
This relationships between the Th17-cytokines EBC level and tumor diameter may support the previous 
observation of Carpagnano on the presence of a relationship between the level of cytokines in EBC and 
stage of disease [23]. The design of our study was planned to select only patients with early-stage disease, 
so that further studies are needed to verify the relationship between IL-17 and the disease stage. 
Our results, for the first time, underline the strict relationship between inflammatory and angiogenic 
markers, measured non-invasively in EBC, and tumor mass. Theoretically, these cytokines could be 
produced either by the tumor itself or by a more extensive tissue infiltration of inflammatory cells. 
Conclusion 
Our data demonstrate that, in the early stages of NSCLC, inflammatory changes are detectable in the 
respiratory system, and that cytokine levels, measured in EBC, but not in serum, correlate with the tumor 
mass. 
Further studies are needed to evaluate the changes in EBC inflammatory markers following surgical 
resection and the clinical usefulness of breath testing in the follow-up of patients with lung cancer. 
Acknowledgment 
This work was supported by Regione Piemonte grant for medical research (grant number 
D15E12007140005) 
The authors have declared no conflicts of interest. 
10 
 
References 
• [1]Ferlay J, Shin H R, Bray F, Forman D, Mathers C and Parkin D M 2010 Estimates of worldwide 
burden of cancer in 2008: GLOBOCAN 2008 Int. J. Cancer 127 2893–917 
• [2]Panico F, Rizzi F, Fabbri L M, Bettuzzi S and Luppi F 2009 Clusterin (CLU) and lung cancer Adv. 
Cancer Res. 105 63–76 
• [3]Konvalina G and Haick H 2013 Sensors for breath testing: from nanomaterials to comprehensive 
disease detection Acc. Chem. Res. 47 66–76 
• [4]Broza Y Y and Haick H 2013 Nanomaterial-based sensors for detection of disease by volatile 
organic compounds Nanomedicine 8 785–806 
• [5]Hakim M, Broza Y Y, Barash O, Peled N, Phillips M, Amann A and Haick H 2012 Volatile organic 
compounds of lung cancer and possible biochemical pathways Chem. Rev. 1125949–66 
• [6]Mantovani A, Allavena P, Sica A and Balkwill F 2008 Cancer-related 
inflammation Nature454 436–44 
• [7]Sethi G, Shanmugam M K, Ramachandran L, Kumar A P and Tergaonkar V 2012 Multifaceted link 
between cancer and inflammation Biosci. Rep. 32 1–15 
• [8]Aggarwal B B and Gehlot P 2009 Inflammation and cancer: how friendly is the relationship for 
cancer patients? Curr. Opin. Pharmacol. 9 351–69 
• [9]Kryczek I et al 2009 Phenotype, distribution, generation, and functional and clinical relevance of 
Th17 cells in the human tumor environments Blood 114 1141–9 
• [10]Martin-Orozco N, Muranski P, Chung Y, Yang X O, Yamazaki T, Lu S, Hwu P, Restifo N P, Overwijk 
W W and Dong C 2009 T helper 17 cells promote cytotoxic T cell activation in tumor 
immunity Immunity 31 787–98 
• [11]Wilke C M, Kryczek I, Wei S, Zhao E, Wu K, Wang G and Zou W 2011 Th17 cells in cancer: help or 
hindrance? Carcinogenesis 32 643–9 
• [12]Ye Z J, Zhou Q, Zhang J C, Xin J B and Shi H Z 2011 CD39+ regulatory T cells suppress generation 
and differentiation of Th17 cells in human malignant pleural effusion via a LAP-dependent 
mechanism Respir. Res. 12 77 
• [13]Zhang Q et al 2012 Interleukin-17 promotes formation and growth of prostate adenocarcinoma 
in mouse models Cancer Res. 72 2589–99 
• [14]Zhang J P, Yan J, Xu J, Pang X H, Pang X H, Chen M S, Li L, Wu C, Li S P and Zheng L 2009 
Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular 
carcinoma patients J. Hepatol. 50 980–9 
• [15]Chen X, Wan J, Liu J, Li X, Wu C, Quin S M, Zhu B and Chen Z 2010 Increased IL-17-producing 
cells correlate with poor survival and lymphangiogenesis in NSCLC patients Lung Cancer 69 348–54 
11 
 
• [16]Numasaki M, Lotze M T and Sasaki H 2004 Interleukin-17 augments tumor necrosis factor-
alpha-induced elaboration of proangiogenic factors from fibroblasts Immunol. Lett. 93 39–43 
• [17]Kato T, Furumoto H, Ogura T, Kamada M and Aono T 2001 Expression of IL-17 mRNA in ovarian 
cancer Biochem. Biophys. Res. Commun. 282 735–8 
• [18]Iida T et al 2011 Tumor-infiltrating CD4+ Th17 cells produce IL-17 in tumor microenvironment 
and promote tumor progression in human gastric cancer Oncol. Rep. 251271–7 
• [19]Numasaki M et al 2005 IL-17 enhances the net angiogenic activity and in vivo growth of human 
non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis J. 
Immunol. 175 6177–89 
• [20]Ferrara N, Gerber HP and LeCouter J 2003 The biology of VEGF and its receptors Nature 
Med. 9 669–76 
• [21]Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, Lin Z and Zhu B 2011 IL-17 is associated with poor 
prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal 
carcinoma Biochem. Biophys. Res. Commun. 407 348–54 
• [22]Hunt J 2007 Exhaled breath condensate- an overview Immunol. Allergy Clin. North Am. 27587–
96 
• [23]Carpagnano G E, Resta O, Foschino-Barbaro M P, Gramiccioni E and Carpagnano F 2002 
Interleukin-6 is increased in breath condensate of patients with non-small cell lung cancer Int. J. 
Biol. Markers 17 141–5 
• [24]Gessner C, Rechner B, Hammerschmidt S, Kuhn H, Hoheisel G, Sack U, Ruschpler P and Wirtz H 
2010 Angiogenic markers in breath condensate identify non-small cell lung cancer Lung 
Cancer 68 177–84 
• [25]Carpagnano G E, Foschino Barbaro M P, Cagnazzo M, Di Gioia G, Giliberti T, Di Matteo C and 
Resta O 2005 Use of exhaled breath condensate in the study of airway inflammation after 
hypertonic saline solution challenge Chest 128 3159–66 
• [26]Charles K A et al 2009 The tumor-promoting actions of TNF-α involve TNF-R1 and IL-17 in 
ovarian cancer in mice and humans J. Clin. Invest. 119 3011–23 
• [27]Chen J et al 2013 A two-SNP IL-6 promoter haplotype is associated with increased lung cancer 
risk J. Cancer Res. Clin. Oncol. 139 231–42 
• [28]Gu F M et al 2011 IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor 
progression in hepatocellular carcinoma Mol. Cancer 10 150–22 
• [29]Sobin L, Gospodarowicz M and Wittekind C 2009 TNM Classification of Malignant Tumours7th 
edn (Chichester: Wiley-Blackwell) 
• [30]Horváth I, Hunt J, Barnes P J and On behalf of the ATS/ERS Task Force on Exhaled Breath 
Condensate 2005 Exhaled breath condensate: methodological recommendations and unresolved 
questions Eur. Respir. J. 26 523–48 
12 
 
• [31]Kastelijn E A, Rijkers G T, Van Moorsel C H, Zanen P, Kwakkel-van Erp J M, Van De Graaf E A, 
Van Kessel D A, Grutters J C and Van Den Bosch J M 2010 Systemic and exhaled cytokine and 
chemokine profiles are associated with the development of bronchiolitis obliterans syndrome J. 
Heart Lung Transplant. 29 997–1008 
• [32]Gannot G, Tangrea M A, Richardson A M, Flaig M J, Hewitt S M, Marcus E M, Emmert-Buck M R 
and Chuaqui R F 2007 Layered expression scanning: multiplex molecular analysis of diverse life 
science platforms Clin. Chim. Acta 376 9–16 
• [33]Scott W J, Howington J, Feigenberg S, Movsas B and Pisters K 2007 Treatment of non-small cell 
lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd 
edition) Chest 132 234S–42S 
• [34]Long J S and Freese J 2006 Models for nominal outcomes with case-specific data Regression 
Models for Categorical Dependent Variables Using Stata (2nd edition) (College Station, TX: Stata 
Press) 
• [35]Rabe-Hesketh S and Skrondal A 2005 Linear random-coefficient and growth-curve 
models Multilevel and Longitudinal Modeling Using Stata (College Station (TX): Stata Press) 
• [36]Goldoni M et al 2013 Concentration of exhaled breath condensate biomarkers after 
fractionated collection based on exhaled CO2 signal J. Breath Res. 7 017101 
• [37]Gessner C, Rechner B, Hammerschmidt S, Kuhn H, Hoheisel G, Sack U, Ruschpler P and Wirtz H 
2010 Angiogenic markers in breath condensate identify non-small cell lung cancer Lung 
Cancer 68 177–84 
• [38]Malerba M and Montuschi P 2012 Non-invasive biomarkers of lung inflammation in smoking 
subjects Curr. Med. Chem. 19 187–96 
• [39]Foschino Barbaro M P, Carpagnano G E, Spanevello A, Cagnazzo M G and Barnes P J 2007 
Inflammation, oxidative stress and systemic effects in mild chronic obstructive pulmonary 
disease Int. J. Immunopathol. Pharmacol. 20 753–63 
• [40]Matsunaga K, Yanagisawa S, Ichikawa T, Ueshima K, Hirano T, Nakanishi M, Yamagata T, 
Minakata Y and Ichinose M 2006 Airway cytokine expression measured by means of protein array in 
exhaled breath condensate: correlation with physiologic properties in asthmatic patients J. Allergy 
Clin. Immunol. 118 84–90 
• [41]Luckheeram R V, Zhou R, Verma A D and Xia B 2012 CD4+ Cells: differentiation and 
functions Clin. Dev. Immunol. 2012 925135 
• [42]Lee Y et al 2012 Induction and molecular signature of pathogenic TH17 cells Nature 
Immunol. 13 991–9 
• [43]Kaminska J, Kowalska M, Kotowicz B, Fuksiewicz M, Glogowski M, Wojcik E, Chechlinska M and 
Steffen J 2006 Pretreatment serum levels of cytokines and cytokine receptors in patients with non-
small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF—an 
independent prognostic factor Oncology 70 115–25 
13 
 
• [44]Peled N, Hakim M, Bunn P A Jr, Miller Y E, Kennedy T C, Mattei J, Mitchell J D, Hirsch F R and 
Haick H 2012 Non-invasive breath analysis of pulmonary nodules J. Thorac. Oncol. 71528–33 
• [45]Yanagawa H, Sone S, Takahashi Y, Haku T, Yano S, Shinohara T and Ogura T 1995 Serum levels 
of interleukin 6 in patients with lung cancer Br. J. Cancer 71 1095–8 
• [46]Pine S R, Mechanic L E, Enewold L, Chaturvedi A K, Katki H A, Zheng Y L, Bowman E D, Engels E 
A, Caporaso N E and Harris C C 2011 Increased levels of circulating interleukin 6, interleukin 8, C-
reactive protein, and risk of lung cancer J. Natl Cancer Inst. 103 1112–22 
Citations 
1. Imputing defensible values for left-censored 'below level of quantitation' (LoQ) biomarker 
measurements 
Joachim D Pleil  2016 Journal of Breath Research  10 045001 
2. Exhaled breath condensate for lung cancer protein analysis: a review of methods and biomarkers 
Sarah A Hayes et al  2016 Journal of Breath Research  10 034001 
3. Exhaled Breath Condensate: Technical and Diagnostic Aspects 
Efstathia M. Konstantinidi et al  2015 The Scientific World Journal  2015 1 
 
